Research & Studies
Share your love
Opthea Completes Enrollment in Wet AMD Phase 3 Trials
Opthea Limited announced the completion of enrollment in both the COAST and ShORe trials, constituting its pivotal Phase 3 clinical program. This program is designed to assess the safety and superior efficacy of sozinibercept in combination with standard-of-care anti-VEGF-A therapies…
Exonate Adds Dr. Rafiq Hasan to Leadership Team
Exonate announced the expansion of its Board with the appointment of Dr. Rafiq Hasan as Non-Executive Director. This strategic move aims to bolster the company’s expertise in ophthalmology, particularly within the diabetic eye disease sector, as it advances its lead…
Exclusive Interview with Prof. Dr. Oliver Findl
*If you are interested in becoming a part of our OBN Spotlight TV series, reach us at info@ophthalmologybreakingnews.com. Q1: As you reflect on the recent ESCRS 2023 Congress, could you share with us the key highlights and breakthroughs in cataract…
Neuron Discovery Guides Retinal Blood Vessel Formation
Scientists at UC San Francisco have identified a novel type of neuron that plays a crucial role in guiding the formation of the intricate lattice of blood vessels in the retina. This lattice is essential for nourishing the cells responsible…
Pegcetacoplan’s Role in Retinal Atrophy Treatment
Researchers from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital and University College London Institute of Ophthalmology, London have conducted a post hoc analysis of data from two phase 3 clinical trials of pegcetacoplan (Syfovre,…
Outlook Therapeutics Seeks UK Approval for Wet AMD Drug
Outlook Therapeutics announced the submission of its Marketing Authorisation Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) in a press release. The MAA is for bevacizumab gamma (ONS-5010/LYTENAVA), its investigational formulation of bevacizumab for the…
Rezolute’s Phase 2 Success with Oral DME Drug
Rezolute announced promising topline results from its Phase 2 clinical study of RZ402. This study targeted patients with diabetic macular edema (DME) who were either naïve to or had limited exposure to anti-vascular endothelial growth factor (anti-VEGF) injections. Monumental Results…
KDB GLIDE FDA 510(k) Clearance for Expanded Glaucoma Use
New World Medical announced a significant milestone with the receipt of 510(k) indication expansion from the U.S. Food and Drug Administration (FDA) for KDB (Kahook Dual Blade) GLIDE. This clearance allows for the reduction of intraocular pressure (IOP) in adult…
HealthyCell Introduces Eye Health MicroGel Supplement
HealthyCell has launched its latest product, Eye Health, a novel ultra-absorbable gel supplement designed to enhance and maintain eye health. This new offering comes at a time when preserving vision is increasingly important due to an aging population and the…
Clearside Biomedical Publishes SCS Delivery Guidelines
Clearside Biomedical has taken a significant step forward in the field of ophthalmology by publishing new guidelines for suprachoroidal space (SCS) injection, a technique used to deliver medication directly to the back of the eye. These guidelines have been featured…